267 related articles for article (PubMed ID: 35476295)
1. Targeting IDH-Mutant Glioma.
Miller JJ
Neurotherapeutics; 2022 Oct; 19(6):1724-1732. PubMed ID: 35476295
[TBL] [Abstract][Full Text] [Related]
2. Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R; de la Fuente MI
Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
[TBL] [Abstract][Full Text] [Related]
3. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
[TBL] [Abstract][Full Text] [Related]
5. Gray Areas in the Gray Matter:
van den Bent MJ; Mellinghoff IK; Bindra RS
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-8. PubMed ID: 32186930
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
7. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
9. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
Richardson LG; Miller JJ; Kitagawa Y; Wakimoto H; Choi BD; Curry WT
Neurosurg Focus; 2022 Feb; 52(2):E6. PubMed ID: 35104795
[TBL] [Abstract][Full Text] [Related]
10. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
11. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
Friedrich M; Bunse L; Wick W; Platten M
Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
[TBL] [Abstract][Full Text] [Related]
12. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
Robinson C; Kleinschmidt-DeMasters BK
J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
[TBL] [Abstract][Full Text] [Related]
14. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
Tang F; Pan Z; Wang Y; Lan T; Wang M; Li F; Quan W; Liu Z; Wang Z; Li Z
Neurosci Bull; 2022 Sep; 38(9):1069-1084. PubMed ID: 35670952
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathogenesis of Low-Grade Glioma.
Bready D; Placantonakis DG
Neurosurg Clin N Am; 2019 Jan; 30(1):17-25. PubMed ID: 30470401
[TBL] [Abstract][Full Text] [Related]
17. Accelerated progression of IDH mutant glioma after first recurrence.
Miller JJ; Loebel F; Juratli TA; Tummala SS; Williams EA; Batchelor TT; Arrillaga-Romany I; Cahill DP
Neuro Oncol; 2019 May; 21(5):669-677. PubMed ID: 30668823
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
19. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics.
Yeo KK; Alexandrescu S; Cotter JA; Vogelzang J; Bhave V; Li MM; Ji J; Benhamida JK; Rosenblum MK; Bale TA; Bouvier N; Kaneva K; Rosenberg T; Lim-Fat MJ; Ghosh H; Martinez M; Aguilera D; Smith A; Goldman S; Diamond EL; Gavrilovic I; MacDonald TJ; Wood MD; Nazemi KJ; Truong A; Cluster A; Ligon KL; Cole K; Bi WL; Margol AS; Karajannis MA; Wright KD
Neuro Oncol; 2023 Jan; 25(1):199-210. PubMed ID: 35604410
[TBL] [Abstract][Full Text] [Related]
20. [Precision Medicine for IDH-mutant Diffuse Glioma(Lower-grade Glioma)].
Mukasa A
No Shinkei Geka; 2022 Jan; 50(1):8-18. PubMed ID: 35169082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
